With their final thoughts, medical experts share unmet needs in the treatment landscape of Ph+ acute lymphoblastic leukemia.
Amanda Przespolewski, DO
Advertisement
Articles by Amanda Przespolewski, DO
Key advances in ALL treatment from ASCO 2023 are discussed by Dr Przespolewski.
Dr Aldoss discusses the role ponatinib and blinatumomab in the management of Ph+ALL.
Medical experts highlight recent findings from the PhALLCON study.
Drs Aldoss and Przespolewski evaluate the changing treatment landscape for patients diagnosed with Ph+ ALL.
Amanda Przespolewski, DO, and Ibrahim Aldoss, MD define and discuss how to diagnose patients with Ph+ALL.
Advertisement
Latest Updated Articles
Recent Updates from the PhALLCON StudyJuly 5th 2023
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Palbociclib Plus Trastuzumab, With/Without Pertuzumab, and ET as Maintenance in HR+, HER2+ Metastatic Breast Cancer
2
Allogeneic BCMA CAR T-Cell Therapy CT0596 Elicits 100% ORR in R/R Myeloma and Plasma Cell Leukemia
3
Tirabrutinib May Shift the R/R PCNSL Treatment Paradigm Toward Improved Tolerability
4
Dr O’Malley on What to Reach for Outside of a Clinical Trial in Platinum-Resistant Ovarian Cancer
5